| Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study DV Parmar, KA Kansagra, JC Patel, SN Joshi, NS Sharma, AD Shelat, ... American Journal of Nephrology 49 (6), 470-478, 2019 | 57 | 2019 |
| Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis R Vuppalanchi, SH Caldwell, N Pyrsopoulos, AS DeLemos, S Rossi, ... Journal of hepatology 76 (1), 75-85, 2022 | 29 | 2022 |
| Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis MS Siddiqui, D Parmar, F Sheikh, SK Sarin, L Cisneros, S Gawrieh, ... Clinical Gastroenterology and Hepatology 21 (10), 2597-2605. e2, 2023 | 13 | 2023 |
| Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients MS Siddiqui, D Parmar, F Shaikh, M Forsgren, S Patel, AT Bui, S Boyett, ... Liver Transplantation 29 (9), 979-986, 2023 | 10 | 2023 |
| A multicenter, open-label, single-arm study to evaluate the efficacy and safety of Saroglitazar in patients with primary biliary cholangitis R Vuppalanchi, MS González-Huezo, R Payan-Olivas, ... Clinical and Translational Gastroenterology 12 (4), e00327, 2021 | 10 | 2021 |
| Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial R Rodriguez-Gutierrez, JG González, D Parmar, F Shaikh, P Cruz-López Journal of Lipid Research 63 (7), 2022 | 5 | 2022 |
| A clinical trial to evaluate the safety and efficacy of saroglitazar compared to fenofibrate in patients with dyslipidemia D Parmar, M Krishnappa, F Arifahmed, N Mali, J Patel, M Shah, K Parmar, ... Atherosclerosis 287, e35-e36, 2019 | 1 | 2019 |
| Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment E Lawitz, D Parmar, T Momin, F Shaikh, H Patel, H Hayes, K Swint Clinical Pharmacology in Drug Development 12 (12), 1142-1155, 2023 | | 2023 |
| METABOLIC FLEXIBILITY PREDICTS RESPONSE TO SAROGLITAZAR TREATMENT IN LIVER TRANSPLANT RECIPIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE MS Siddiqui, DMV Parmar, F Shaikh, N Shaikh, A Bui, V Patel, A Sanyal HEPATOLOGY 78, S361-S362, 2023 | | 2023 |
| Efficacy and safety of saroglitazar 4 mg compared to fenofibrate 160 mg in latino adults with moderate to severe hypertriglyceridemia-a randomized clinical trial D Parmar, R Rodriguez-Gutierrez, JG González-González, F Shaikh, ... Atherosclerosis 355, 257, 2022 | | 2022 |
| SAROGLITAZAR REDUCES HEPATIC STEATOSIS IN LIVER TRANSPLANT RECIPIENTS WITH NAFLD: INTERIM RESULTS FROM A PHASE 2A TRIAL MS Siddiqui, FA Shaikh, AJ Sanyal, J Bainbridge, T Syed, VA Luketic, ... HEPATOLOGY 74 (6), 1407A-1408A, 2021 | | 2021 |
| SAROGLITAZAR ON IMPROVES ATHEROGENIC LIPOPROTEIN PROFILE IN LIVER TRANSPLANT RECIPIENTS MS Siddiqui, FA Shaikh, AJ Sanyal, J Bainbridge, T Syed, VA Luketic, ... HEPATOLOGY 74 (6), 1408A-1408A, 2021 | | 2021 |
| Saroglitazar magnesium improves lipid parameters in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis D Parmar, S Gawrieh, K Cusi, N Chalasani, LEC Garza, C Bihari, ... Atherosclerosis 315, e47, 2020 | | 2020 |
Arun Sanyal在 mcvh-vcu.edu 的电子邮件经过验证
